• 1
    Green PH, Cellier C. Celiac disease. N Engl J Med. 2007; 357: 1731-1743.
  • 2
    Telega G, Bennet TR, Werlin S. Emerging new clinical patterns in the presentation of celiac disease. Arch Pediatr Adolesc Med. 2008; 162: 164-168.
  • 3
    Green PH. Mortality in celiac disease, intestinal inflammation, and gluten sensitivity. JAMA. 2009; 302: 1225-1226.
  • 4
    Murray JA, Van Dyke C, Plevak MF, Dierkhising RA, Zinsmeister AR, Melton LJ 3rd. Trends in the identification and clinical features of celiac disease in a North American community, 1950-2001. Clin Gastroenterol Hepatol. 2003; 1: 19-27.
  • 5
    Green PH, Neugut AI, Naiyer AJ, Edwards ZC, Gabinelle S, Chinburpa V. Economic benefits of increased diagnosis of celiac disease in a national managed care population in the United States. J Insur Med. 2008; 40: 218-228.
  • 6
    Catassi C, Kryszak D, Bhatti B, et al. Natural history of celiac disease autoimmunity in a USA cohort followed since 1974. Ann Med. 2010; 42: 530-538.
  • 7
    Rubio-Tapia A, Kyle RA, Kaplan EL, et al. Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology. 2009; 137: 88-93.
  • 8
    Grainge MJ, West J, Card TR, Holmes GK. Causes of death in people with celiac disease spanning the pre- and post-serology era: a population-based cohort study from Derby, UK. Am J Gastroenterol. 2011; 106: 933-939.
  • 9
    Ludvigsson JF, Montgomery SM, Ekbom A, Brandt L, Granath F. Small-intestinal histopathology and mortality risk in celiac disease. JAMA. 2009; 302: 1171-1178.
  • 10
    Green PH, Fleischauer AT, Bhagat G, Goyal R, Jabri B, Neugut AI. Risk of malignancy in patients with celiac disease. Am J Med. 2003; 115: 191-195.
  • 11
    Domizio P, Owen RA, Shepherd NA, Talbot IC, Norton AJ. Primary lymphoma of the small intestine. A clinicopathological study of 119 cases. Am J Surg Pathol. 1993; 17: 429-442.
  • 12
    Otter R, Bieger R, Kluin PM, Hermans J, Willemze R. Primary gastrointestinal non-Hodgkin's lymphoma in a population-based registry. Br J Cancer. 1989; 60: 745-750.
  • 13
    O'Farrelly C, Feighery C, O'Briain DS, et al. Humoral response to wheat protein in patients with coeliac disease and enteropathy associated T cell lymphoma. Br Med J (Clin Res Ed). 1986; 293: 908-910.
  • 14
    A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997; 89: 3909-3918.
  • 15
    Smedby KE, Akerman M, Hildebrand H, Glimelius B, Ekborn A, Askling J. Malignant lymphomas in coeliac disease: evidence of increased risks for lymphoma types other than enteropathy-type T cell lymphoma. Gut. 2005; 54: 54-59.
  • 16
    Mearin ML, Catassi C, Brousse N, et al; Biomed Study Group on Coeliac Disease and Non-Hodgkin Lymphoma. European multi-centre study on coeliac disease and non-Hodgkin lymphoma. Eur J Gastroenterol Hepatol. 2006; 18: 187-194.
  • 17
    Catassi C, Fabiani E, Corrao G, et al; Italian Working Group on Coeliac Disease and Non-Hodgkin's Lymphoma. Risk of non-Hodgkin lymphoma in celiac disease. JAMA. 2002; 287: 1413-1419.
  • 18
    Verbeek WH, Van De Water JM, Al-Toma A, Oudejans JJ, Mulder CH, Coupe VM. Incidence of enteropathy-associated T-cell lymphoma: a nation-wide study of a population-based registry in the Netherlands. Scand J Gastroenterol. 2008; 43: 1322-1328.
  • 19
    van de Water JM, Cillessen SA, Visser OK, Verbeek WH, Meijer CJ, Mulder CJ. Enteropathy associated T-cell lymphoma and its precursor lesions. Best Pract Res Clin Gastroenterol. 2010; 24: 43-56.
  • 20
    National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER). Bethesda, MD: National Cancer Institute; 2011. Available at: [Accessed on November 7, 2011.]
  • 21
    Gale J, Simmonds PD, Mead GM, Sweetenham JW, Wright DH. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol. 2000; 18: 795-803.
  • 22
    Delabie J, Holte H, Vose JM et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project. Blood. 2011; 118: 148-155.
  • 23
    Malamut G, Afchain P, Verkarre V, et al. Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology. 2009; 136: 81-90.
  • 24
    Daum S, Ipczynski R, Schumann M, Wahnschaffe U, Zeitz M, Ullrich R. High rates of complications and substantial mortality in both types of refractory sprue. Eur J Gastroenterol Hepatol. 2009; 21: 66-70.
  • 25
    Roshan B, Leffler DA, Jamma S, et al. The incidence and clinical spectrum of refractory celiac disease in a North American referral center. Am J Gastroenterol. 2011; 106: 923-928.
  • 26
    Malamut G, Cellier C. Is refractory celiac disease more severe in old Europe? Am J Gastroenterol. 2011; 106: 929-932.
  • 27
    Johnson TC, Diamond B, Memeo L, et al. Relationship of HLA-DQ8 and severity of celiac disease: comparison of New York and Parisian cohorts. Clin Gastroenterol Hepatol. 2004; 2: 888-894.
  • 28
    Ferreri AJ, Zinzani PL, Govi S, Pileri SA. Enteropathy-associated T-cell lymphoma. Crit Rev Oncol Hematol. 2011; 79: 84-90.
  • 29
    Sieniawski M, Angamuthu N, Boyd K, et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood. 2010; 115: 3664-3670.
  • 30
    Schweizer JJ, von Blomberg BM, Bueno-de Mesquita HB, Mearin ML. Coeliac disease in the Netherlands. Scand J Gastroenterol. 2004; 39: 359-364.
  • 31
    Bai D, Brar P, Holleran S, Ramakrishnan R, Green PH. Effect of gender on the manifestations of celiac disease: evidence for greater malabsorption in men. Scand J Gastroenterol. 2005; 40: 183-187.
  • 32
    Fasano A, Berti I, Gerarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med. 2003; 163: 286-292.
  • 33
    Holmes GK, Prior P, Lane MR, Pope D, Allan RN. Malignancy in coeliac disease—effect of a gluten free diet. Gut. 1989; 30: 333-338.
  • 34
    Araya M, Mondragon A, Perez-Bravo F, et al. Celiac disease in a Chilean population carrying Amerindian traits. J Pediatr Gastroenterol Nutr. 2000; 31: 381-386.
  • 35
    Gandolfi L, Pratesi R, Cordoba JC, Tauil PL, Gasparin M, Catassi C. Prevalence of celiac disease among blood donors in Brazil. Am J Gastroenterol. 2000; 95: 689-692.
    Direct Link:
  • 36
    Remes-Troche JM, Ramirez-Iglesias MT, Rubio-Tapia A, Alonso-Ramos A, Velazquez A, Uscanga LF. Celiac disease could be a frequent disease in Mexico: prevalence of tissue transglutaminase antibody in healthy blood donors. J Clin Gastroenterol. 2006; 40: 697-700.
  • 37
    Gomez JC, Selvaggio GS, Viola M, et al. Prevalence of celiac disease in Argentina: screening of an adult population in the La Plata area. Am J Gastroenterol. 2001; 96: 2700-2704.
    Direct Link:
  • 38
    Chan JK, Chan AC, Cheuk W, et al. Type II enteropathy-associated T-cell lymphoma: a distinct aggressive lymphoma with frequent gammadelta T-cell receptor expression. Am J Surg Pathol. 2011; 35: 1557-1569.
  • 39
    Chuang SS, Liao YL, Liu H, et al. The phenotype of intraepithelial lymphocytes in Taiwanese enteropathy-associated T-cell lymphoma is distinct from that of the west. Histopathology. 2008; 53: 234-236.
  • 40
    Ko YH, Karnan S, Kim KM, et al. Enteropathy-associated T-cell lymphoma—a clinicopathologic and array comparative genomic hybridization study. Hum Pathol. 2010; 41: 1231-1237.
  • 41
    Garcia-Herrera A, Sing JY, Chuang SS, et al. Nonhepatosplenic gammadelta T-cell lymphomas represent a spectrum of aggressive cytotoxic T-cell lymphomas with a mainly extranodal presentation. Am J Surg Pathol. 2011; 35: 1214-1225.